COVID-19 nanoparticle vaccine candidate
Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Virus-like particles |
Clinical data | |
Routes of administration | Intramuscular |
IVX-411 is a COVID-19 candidate nanoparticle vaccine under development by Icosavax currently undergoing a Phase I/II clinical trial in Australia.[1] It was originally developed at the Institute of Protein Design (IPD) and the University of Washington School of Medicine, both based at the University of Washington.[2][3][4]
Part of a series on the |
COVID-19 pandemic |
---|
![]() |
|
Medical response |
|
![]() |
References
[edit]- ^ "ANZCTR - Registration". anzctr.org.au. Retrieved 18 August 2021.
- ^ "Icosavax Initiates Phase 1/2 Trial of COVID-19 VLP Vaccine Candidate - Icosavax, Inc". investors.icosavax.com. Retrieved 18 August 2021.
- ^ "Two nanoparticle vaccines enter clinical trials". Institute for Protein Design. 2 June 2021. Retrieved 18 August 2021.
- ^ Arunachalam PS, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, et al. (June 2021). "Adjuvanting a subunit COVID-19 vaccine to induce protective immunity". Nature. 594 (7862): 253–258. Bibcode:2021Natur.594..253A. doi:10.1038/s41586-021-03530-2. PMID 33873199.
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|